Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings ...

Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

On Monday, Canaccord Genuity adjusted its price target for 10X Genomics (NASDAQ:TXG) shares, lowering it to $15.00 from the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest price target for 10x Genomics (NASDAQ:TXG) was reported by Morgan Stanley on May 19, 2025. The analyst firm set a price target for $18.00 expecting TXG to rise to within 12 months (a ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...